Adrian Gottschlich
Overview
Explore the profile of Adrian Gottschlich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nowotny H, Zheng T, Seiter T, Ju J, Schneider H, Kroiss M, et al.
Front Immunol
. 2025 Jan;
15:1428054.
PMID: 39749333
Background: High dietary sodium intake is a major cardiovascular risk factor and adversely affects blood pressure control. Patients with primary aldosteronism (PA) are at increased cardiovascular risk, even after medical...
2.
Pekayvaz K, Losert C, Knottenberg V, Gold C, van Blokland I, Oelen R, et al.
Nat Med
. 2024 May;
30(6):1696-1710.
PMID: 38773340
Acute and chronic coronary syndromes (ACS and CCS) are leading causes of mortality. Inflammation is considered a key pathogenic driver of these diseases, but the underlying immune states and their...
3.
Tsiverioti C, Gottschlich A, Trefny M, Theurich S, Anders H, Kroiss M, et al.
Biol Chem
. 2024 May;
405(7-8):485-515.
PMID: 38766710
Chimeric antigen receptor (CAR)-T cell therapy has led to remarkable clinical outcomes in the treatment of hematological malignancies. However, challenges remain, such as limited infiltration into solid tumors, inadequate persistence,...
4.
Stock S, Fertig L, Gottschlich A, Dorr J, Markl F, Majed L, et al.
Cancer Immunol Immunother
. 2024 Apr;
73(6):100.
PMID: 38630291
In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T cells with a...
5.
Xhaxho S, Chen-Wichmann L, Kreissig S, Windisch R, Gottschlich A, Nandi S, et al.
Transfus Med Hemother
. 2024 Apr;
51(2):111-118.
PMID: 38584695
Introduction: Primary human blood cells represent an essential model system to study physiology and disease. However, human blood is a limited resource. During healthy donor plateletpheresis, the leukoreduction system chamber...
6.
Nowotny H, Seiter T, Ju J, Gottschlich A, Schneider H, Zopp S, et al.
Front Immunol
. 2023 Dec;
14:1275828.
PMID: 38045693
Introduction: Patients with primary adrenal insufficiency (PAI) suffer from increased risk of infection, adrenal crises and have a higher mortality rate. Such dismal outcomes have been inferred to immune cell...
7.
Wagenbauer K, Pham N, Gottschlich A, Kick B, Kozina V, Frank C, et al.
Nat Nanotechnol
. 2023 Aug;
18(11):1319-1326.
PMID: 37591933
Multispecific antibodies have emerged as versatile therapeutic agents, and therefore, approaches to optimize and streamline their design and assembly are needed. Here we report on the modular and programmable assembly...
8.
Markl F, Benmebarek M, Keyl J, Cadilha B, Geiger M, Karches C, et al.
J Immunother Cancer
. 2023 May;
11(5).
PMID: 37208128
Background: Melanoma is an immune sensitive disease, as demonstrated by the activity of immune check point blockade (ICB), but many patients will either not respond or relapse. More recently, tumor...
9.
Gottschlich A, Thomas M, Grunmeier R, Lesch S, Rohrbacher L, Igl V, et al.
Nat Biotechnol
. 2023 Mar;
41(11):1618-1632.
PMID: 36914885
Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment option for individuals with B cell malignancies but have yet to achieve success in treating acute myeloid...
10.
Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou A, Schubel M, et al.
Immunity
. 2023 Jan;
56(1):143-161.e11.
PMID: 36630913
Although T cells can exert potent anti-tumor immunity, a subset of T helper (Th) cells producing interleukin-22 (IL-22) in breast and lung tumors is linked to dismal patient outcome. Here,...